Pharmos Corporation Announces Results of Phase 2b Irritable Bowel Syndrome Study

September 14, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

ISELIN, N.J., Sept. 14 /PRNewswire-FirstCall/ -- Pharmos Corporation (Pink Sheets: PARS) announced today the results of its Phase 2b Dextofisopam clinical trial to evaluate safety and efficacy of the compound in irritable bowel syndrome.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase II